A different way to reach your patients' LDL-C goals
LEROCHOL is a PCSK9i that’s designed to lower LDL-C
and fit into your patient’s life, not the other way around.
coming soon
- Robust, sustained LDL-C lowering up to 60%1–3*
- Single, small-volume injection (300 mg/1.2 mL)1
- A once-monthly, self-administered, subcutaneous injection2
- Extended room temperature storage for up to 3 months2†
- Small, potent PCSK9-binding protein with high solubility1,2
PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor.
*Indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia,
including HeFH.1
†If LEROCHOL is not refrigerated for more than 3 months, it must be discarded.1
The role of PCSK9 in hepatic LDL receptor activity and plasma LDL-C clearance
-
PCSK9 and LDL-C bind to the LDL receptor1,2
-
The receptor is then internalized into the hepatocyte via endocytosis. However, PCSK9 prevents the normal recycling process of the LDL receptor1,2
-
Instead of recycling back to liver cell surface to remove and deliver more LDL-C, the LDL receptor is targeted for degradation.1,2
With fewer LDL receptors recycled to the surface, there are fewer available to clear LDL-C from the blood1,2
LEROCHOL®: A unique antibody-mimetic recombinant fusion protein specifically designed to bind to and inactivate all circulating PCSK93
-
LEROCHOL binds to PCSK9, inactivating it and thereby preventing its binding to the LDL receptor3
-
LDL-C and the receptor are internalized into the hepatocyte as intended1,2
-
The LDL receptor is recycled back to the cell surface, a process that can happen ~100 times, allowing it to clear more LDL-C from the blood1-3
By inactivating all circulating PCSK9, LEROCHOL increases the number of LDL receptors available to clear LDL-C from the blood to lower LDL-C levels.3
References: 1. Shapiro MD, Tavori H, Fazio S. PCSK9: From basic science discoveries to clinical trials. Circ Res. 2018;122(10):1420-1438. 2. Garwood CL, Cabral KP, Brown R, Dixon DL. Current and emerging PCSK9-directed therapies to reduce LDL-C and ASCVD risk: A state-of-the-art review. Pharmacotherapy. 2025;45(1):54-65. 3. Lerochol [prescribing information]. LIB Therapeutics; 2026.
PRO-1137-v1 09/26
Current Multisociety
Guidelines recommend earlier
and
more aggressive LDL-C
lowering, particularly for
patients with FH
| 2026 ACC/AHA/ Multisociety Guidelines on the Management of Dyslipidemia4 | ESC/ EAS 20255 | |
|---|---|---|
| High Risk | <70 mg/dL; statin ± nonstatin Consider PCSK9i if LDL-C remains above threshold despite statin and ezetimibe | <70 mg/dL + ≥50% reduction |
| Very High Risk | <55 mg/dL; (very high risk); stepwise: statin → ezetimibe PCSK9i strongly recommended if not | <55 mg/dL + ≥50% reduction |
| HeFH | Add PCSK9i if LDL ≥100 mg/dL despite statin + ezetimibe Early use common, especially with | Treat as high/very high risk; LDL <55–70 depending on phenotype |
Access the complete
2026 ACC/AHA/Multisociety Guideline
on the Management of Dyslipidemia
here.
The ACC/AHA/Multisociety includes the following organizations: ACC, AHA, AACVPR, ABC, ACPM, ADA, AGS, APhA, ASPC, NLA, and PCNA.
AACVPR, American Association of Cardiovascular and Pulmonary Rehabilitation; ABC, Association of Black Cardiologists; ACC, American College of Cardiology; ACPM, American College of Preventative Medicine; ADA, American Diabetes Association; AGS, American Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASPC, American Society for Preventive Cardiology; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; ASCVD, atherosclerotic cardiovascular disease; HeFH, heterozygous familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; mAb, monoclonal antibody; NLA, National Lipid Association; PCNA, Preventive Cardiovascular Nurses Association; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor.
References: 1. Lerochol [prescribing information]. LIB Therapeutics; 2026. 2. Klug EQ, Llerena S, Burgess LJ, et al. Efficacy and safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial. JAMA Cardiol. 2024;9(9):800-807. 3. Raal F, Fourie N, Scott R, et al. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J. 2023;44(40):4272-4280. 4. Blumenthal RS, et al. J Am Coll Cardiol. 2026 (In Press): https://pubmed.ncbi.nlm.nih.gov/41824590/. 5. Mach F, et al. Eur Heart J. 2025;46(42):4359-4378.